Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
In traditional medicine, Cannabis sativa has been prescribed for a variety of diseases. Today, the plant is largely known for its recreational purpose, but it may find a way back to what it was originally known for: a herbal remedy. Most of the plant's ingredients, such as Δ 9-tetrahydrocannabinol, cannabidiol, cannabigerol, and others, have demonstrated beneficial effects in preclinical models of intestinal inflammation. Endogenous cannabinoids (endocannabinoids) have shown a regulatory role in inflammation and mucosal permeability of the gastrointestinal tract where they likely interact with the gut microbiome. Anecdotal reports suggest that in humans, Cannabis exerts antinociceptive, anti-inflammatory, and antidiarrheal properties. Despite these reports, strong evidence on beneficial effects of Cannabis in human gastrointestinal diseases is lacking. Clinical trials with Cannabis in patients suffering from inflammatory bowel disease (IBD) have shown improvement in quality of life but failed to provide evidence for a reduction of inflammation markers. Within the endogenous opioid system, mu opioid receptors may be involved in anti-inflammation of the gut. Opioids are frequently used to treat abdominal pain in IBD; however, heavy opioid use in IBD is associated with opioid dependency and higher mortality. This review highlights latest advances in the potential treatment of IBD using Cannabis/cannabinoids or opioids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224 · cited 1×
“Long-term Cannabis use increases the risk of psychotic outcomes (57) and of cardiovascular (58) and lung diseases (59).”
BackgroundCannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 2×
“Dizziness, dry mouth, nausea, somnolence, and euphoria were the most common short-term side effects; however, anxiety and hallucinations also occurred (52).”
BackgroundOpioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects
Furlan, A. D. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051528 · Cited by 873
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793 · cited 1×
“observation for the presence of ECS-microbiota interaction is that Lactobacillus acidophilus induced CB2 receptor expression in intestinal epithelial cells and in the rodent gut mucosa (46).”
BackgroundThe endocannabinoid system links gut microbiota to adipogenesis
Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691 · cited 2×
“ECS and microbiota Studies of adipogenesis and obesity have revealed a link between the ECS and the microbiome (41,42).”
BackgroundKang, C.-S., Ban, M., Choi, E.-J., Moon, H.-G., Jeon, J.-S., Kim, D.-K., Park, S.-K., Jeon, S. G., Roh, T.-Y., Myung, S.-J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076520 · Cited by 543 · cited 1×
“CB1 antagonists improved diet-induced metabolic dysfunction correlating with an increase in Akkermansia municiphila (43)—a strain known to have beneficial effects in the dextrane sulfate sodium (DSS)-induced colitis model (44).”
BackgroundEndocannabinoids–at the crossroads between the gut microbiota and host metabolism
Cani, P. D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N. M., Druart, C., & Everard, A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.211 · Cited by 367 · cited 1×
“ECS and microbiota Studies of adipogenesis and obesity have revealed a link between the ECS and the microbiome (41,42).”
BackgroundSiegel, D. A., Jatlaoui, T. C., Koumans, E. H., Kiernan, E. A., Layer, M., Cates, J. E., Kimball, A., Weissman, D. N., Petersen, E. E., Reagan-Steiner, S., et al. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6841e3 · Cited by 265
Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0218-8 · Cited by 171 · cited 1×
“In this context, nabilone, a THC analogue, decreased spasticityrelated pain in a clinical trial at a dose as low as 1mg/d causing only mild but well-tolerable side effects (53).”
Background
Cited by
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Lowe, H., Toyang, N., Steele, B., Bryant, J., & Ngwa, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179472 · Cited by 303
Role of the endocannabinoid system in the regulation of intestinal homeostasis
Cuddihey, H., MacNaughton, W. K., & Sharkey, K. A. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.05.015 · Cited by 79
Traditional uses of Cannabis: An analysis of the CANNUSE database
Balant, M., Gras, A., Ruz, M., Vallès, J., Vitales, D., & Garnatje, T. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114362 · Cited by 58
The microbiome and gut endocannabinoid system in the regulation of stress responses and metabolism
Srivastava, R. K., Lutz, B., & Ruiz de Azua, I. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.867267 · Cited by 56
Metadata
- Authors
- Kienzl, M., Storr, M., & Schicho, R.
- Venue
- Clinical and Translational Gastroenterology
- Published
- 2020-01
- Volume
- 11
- Issue
- 1
- Pages
- e00120
- ISSN
- 2155-384X (ISSN-L)
- OpenAlex
- W2997419110
- Cited by
- 56
- References
- 10
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. https://app.cochat.ai/papers/10.14309/ctg.0000000000000120
- The paper
- Kienzl, M., Storr, M., & Schicho, R. (2020). Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology. https://doi.org/10.14309/ctg.0000000000000120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.